Should live vaccine schedules be adjusted after cosentyx?

Official Guidance on Live Vaccines with Cosentyx

Cosentyx (secukinumab), an IL-17 inhibitor for psoriasis, psoriatic arthritis, and ankylosing spondylitis, suppresses immune responses. Its prescribing information states: Avoid live vaccines during treatment. Live vaccines include MMR, varicella (chickenpox), oral polio, yellow fever, and rotavirus.[1]

When to Adjust Live Vaccine Schedules

• Before starting Cosentyx: Complete all age-appropriate live vaccines at least 4 weeks prior. This allows immune response development before immunosuppression.[1][2]
  
• During treatment: Do not administer live vaccines. Non-live (inactivated) vaccines, like flu shots or Tdap, are safe and recommended.[1]
  
• After stopping Cosentyx: Wait 4-6 weeks before giving live vaccines, as drug levels drop and immune function recovers. Timing depends on dose and patient factors—consult a doctor for blood tests if needed.[1][3]
  
  

Why the Adjustment Is Needed

Cosentyx reduces T-cell activity, impairing the body's ability to fight live attenuated viruses. This risks disseminated infection, as seen in biologic trials and post-marketing reports with similar drugs.[2][4] No major patent issues affect this (Cosentyx patents expire around 2032 in the US[5]); guidance stems from pharmacology and FDA/EMA labels.

Exceptions and Special Cases

• Infants of treated mothers: Breastfeeding mothers on Cosentyx should delay infant live vaccines (e.g., rotavirus) until 4-6 weeks post-delivery or after drug clearance.[1]
  
• Travel requirements: For yellow fever or other live travel vaccines, pause Cosentyx or seek infectious disease specialist input—risk vs. benefit weighs disease exposure.[3]
  
• COVID-19 vaccines: All approved versions are non-live mRNA or viral vector, so no adjustment needed.[6]
  
  

Practical Steps for Patients and Providers

Update schedules via CDC or equivalent guidelines, prioritizing non-live options. Annual flu and pneumococcal vaccines remain standard. Monitor for infections during treatment—report fever or rash promptly.[2]

Sources
[1]: Cosentyx Prescribing Information (Novartis)
[2]: CDC Biologics and Immunization Guidelines
[3]: ACR Guidelines on Vaccinations in Rheumatic Diseases
[4]: FDA Adverse Event Reporting System (FAERS) summaries
[5]: DrugPatentWatch.com - Cosentyx Patents
[6]: CDC COVID-19 Vaccine Info